PENTIXAPHARM HOLDING AG (PTP.DE) Stock Overview
Europe - FRA:PTP - DE000A40AEG0 - Common Stock
PTP.DE Key Statistics, Chart & Performance
The current stock price of PTP.DE is 1.666 EUR. In the past month the price decreased by -9.06%. In the past year, price decreased by -53.79%.
PTP.DE Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| 1EL.MI | ESSILORLUXOTTICA | 46.1 | 146.68B | ||
| EL.PA | ESSILORLUXOTTICA | 46.22 | 147.05B | ||
| ESL.DE | ESSILORLUXOTTICA | 45.25 | 143.99B | ||
| 2U3.DE | ALCON INC | 25.04 | 32.41B | ||
| 1ALC.MI | ALCON INC | 24.71 | 31.98B | ||
| CBHD.DE | COLOPLAST-B | 31.68 | 16.98B | ||
| AFW.DE | ALIGN TECHNOLOGY INC | 14.41 | 8.44B | ||
| GENT.OL | GENTIAN DIAGNOSTICS ASA | 20.82 | 863.52M | ||
| GBT.PA | GUERBET | 26.33 | 203.00M | ||
| ALCJ.PA | CROSSJECT | N/A | 124.06M | ||
| AFME.PA | AFFLUENT MEDICAL SA | N/A | 56.47M | ||
| SVS.MI | SVAS BIOSANA SPA | 7.24 | 51.52M |
Related stock screener links
About PTP.DE
Company Profile
Pentixapharm Holding AG engages in the development of radiopharmaceutical approaches for diagnostic and therapeutic programs in a number of hematological and solid cancers, as well as cardiovascular, endocrine, and inflammatory diseases. The company is headquartered in Berlin, Berlin and currently employs 64 full-time employees. The company went IPO on 2024-10-03. The firm focuses on the development of radiopharmaceuticals for various therapeutic areas, as well as for the diagnosis and therapy (theranostics) of blood cancer and others. The company is also engaged in holding activities and is also involved in the research and development of drugs for hematological and solid cancers, as well as cardiovascular, endocrine and inflammatory diseases.
Company Info
PENTIXAPHARM HOLDING AG
Robert-Roessle-Strasse 10
Berlin BERLIN DE
Employees: 64
Phone: 493094893220
PENTIXAPHARM HOLDING AG / PTP.DE FAQ
What does PENTIXAPHARM HOLDING AG do?
Pentixapharm Holding AG engages in the development of radiopharmaceutical approaches for diagnostic and therapeutic programs in a number of hematological and solid cancers, as well as cardiovascular, endocrine, and inflammatory diseases. The company is headquartered in Berlin, Berlin and currently employs 64 full-time employees. The company went IPO on 2024-10-03. The firm focuses on the development of radiopharmaceuticals for various therapeutic areas, as well as for the diagnosis and therapy (theranostics) of blood cancer and others. The company is also engaged in holding activities and is also involved in the research and development of drugs for hematological and solid cancers, as well as cardiovascular, endocrine and inflammatory diseases.
What is the current price of PTP stock?
The current stock price of PTP.DE is 1.666 EUR. The price decreased by -0.48% in the last trading session.
Does PENTIXAPHARM HOLDING AG pay dividends?
PTP.DE does not pay a dividend.
What is the ChartMill rating of PENTIXAPHARM HOLDING AG stock?
PTP.DE has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Can you provide the PE ratio for PTP stock?
PENTIXAPHARM HOLDING AG (PTP.DE) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.69).
What is the ownership structure of PENTIXAPHARM HOLDING AG (PTP.DE)?
You can find the ownership structure of PENTIXAPHARM HOLDING AG (PTP.DE) on the Ownership tab.
PTP.DE Technical Analysis
PTP.DE Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to PTP.DE. No worries on liquidiy or solvency for PTP.DE as it has an excellent financial health rating, but there are worries on the profitability.
PTP.DE Financial Highlights
Over the last trailing twelve months PTP.DE reported a non-GAAP Earnings per Share(EPS) of -0.69.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -41.54% | ||
| ROE | -51.74% | ||
| Debt/Equity | 0 |
PTP.DE Forecast & Estimates
5 analysts have analysed PTP.DE and the average price target is 11.95 EUR. This implies a price increase of 617.55% is expected in the next year compared to the current price of 1.666.